In-house solution for CHO clone selection
Accelerating time to clinic by de-risking clone selection early in the CHO cell line development process
In addition to Cergentis' TLA-based services for Chinese Hamster Ovary (CHO) clone selection, we now offer
a new in-house solution: CHOice®.
This allows our customers to access the same high-quality results while profiting from even shorter turnaround times, cost-efficiency, scalability and confidentiality.
CHO clone selection
Selecting the clone with the preferred genetic make-up is a crucial step in the cell line development process toward producing stable and high-quality biotherapeutic proteins. Cergentis' TLA-based services have a proven track record in the genetic QC and characterization of cell lines and in clone selection. Conventional technologies are limited when it comes to sensitivity, cost and turnaround time. Our TLA-based analysis yields all essential genetic characteristics in a single test: an ideal platform to monitor important quality parameters for clone selection.
Deselecting clones containing undesired mutations in the coding sequence of GOI
De-risking clones early in the cell line development proces
Facilitating early phase testing
Minimizing time to clinic
The in-house solution for CHO clone selection combines the widely-published and recognized TLA analysis with our newly developed software platform.
Integrated solution from sample processing up to analysis
More cost effective than outsourcing and at larger throughput
Reduced turnaround time (7 - 14 days from sample to results)
Master your own data and materials
User friendly and independent of Cergentis' capacity
Automated, unbiased data analysis
Highest quality standard
Fully integrated solution, starting from €9,900
The fully integrated in-house solution CHOice® comprises of the following:
Reagents kit for 12 samples
Access to Cergentis' software analysis platform
Customer & tech support
* First time users will undergo a qualification trajectory including both wetlab and data analysis training.